Patent Landscape and Claim Scope for U.S. Patent 4,677,191
What does U.S. Patent 4,677,191 cover in scope?
Disclosed in 1987, U.S. Patent 4,677,191 pertains to a pharmaceutical composition comprising a bisphosphonate compound. The patent primarily claims the chemical structure, methods of producing the compound, and therapeutic use, specifically targeting bone-resorption diseases. The patent's scope concentrates on a class of bisphosphonate derivatives characterized by specific chemical groups, notably including clodronate and its analogs, and their application in inhibiting bone resorption.
Claim Analysis
-
Core claims (Claims 1-5): Cover a class of bisphosphonate compounds with a general formula, emphasizing specific substituents that confer anti-resorptive activity. The claims specify substitution patterns on phosphorus atoms and on the organic backbone, which determine potency and pharmacokinetics.
-
Manufacturing claims (Claims 6-8): Cover methods for synthesizing these bisphosphonate compounds, utilizing solvolysis reactions and other chemical transformation techniques typical for phosphorus chemistry.
-
Therapeutic use claims (Claims 9-13): Claim the application of the compounds for treating and preventing bone diseases such as osteoporosis, Paget’s disease, and hypercalcemia. These claims include both prophylactic and therapeutic administration routes.
-
Dependent claims: Narrow the scope to specific compounds, dosage forms, and treatment regimens, often referencing particular substituents or salts of the compounds.
Patent Scope Limitations
The patent's claims are limited to compounds with specific phosphorus-containing frameworks and substitution patterns. Claims do not extend broadly to all bisphosphonates but focus on a subset with defined chemical characteristics. The therapeutic claims encompass diseases related to abnormal bone resorption but do not specify indications outside this domain.
Patents That Overlap or Compete
The patent landscape around bisphosphonates has evolved significantly since 1987. Key patents include:
| Patent Number |
Title |
Assignee |
Filing Date |
Claims Scope |
Relationship to 4,677,191 |
| US 5,043,342 |
New Bisphosphonate Compounds |
Procter & Gamble |
1987 |
Similar class, broader substitution scope |
Shares chemical class but broader claims |
| US 4,876,242 |
Treatment of Bone Disorders with Bisphosphonates |
Merck & Co. |
1987 |
Focus on specific compounds and treatment methods |
Overlaps in therapeutic claims |
| US 4,927,814 |
Use of Nitrogen-Containing Bisphosphonates |
Eli Lilly |
1988 |
Nitrogen-containing analogs, different class focus |
Different chemical focus but similar therapeutic application |
The landscape has seen extensive patenting around specific chemical modifications, formulations, and indications, resulting in a dense patent landscape with potential for infringement or design-around strategies.
Trends and Ecosystem
-
Chemical diversification: Since 1987, the development of nitrogen-containing bisphosphonates (e.g., alendronate, zoledronic acid) expanded the scope beyond the compounds claimed in the original patent.
-
Patent expirations: Several foundational patents, including U.S. 4,677,191, have expired or are near expiration, opening markets for generics.
-
Formulation innovations: New patents focus on delivery systems, such as injectable formulations, to improve bioavailability and compliance.
-
Method of use patents: Companies have filed patents covering specific dosing regimens, combination therapies, and indications like bone metastasis.
Impact on Current Innovation and Market
U.S. Patent 4,677,191 establishes a key initial claim set for bisphosphonates' chemical class. Its expiration in 2004 (a 17-year term from grant) allowed generics to enter the market, increasing drug accessibility and competition. Subsequent patents build on this foundation, focusing more on specific compounds, new indications, and formulations.
The current patent landscape contains numerous follow-on patents, many now expired or close to expiration, making the area highly competitive. Innovation emphasis has shifted toward novel bisphosphonates with improved efficacy and safety profiles, as well as new delivery methods.
Strategic Considerations
-
Combining knowledge of the expired patents with newer innovations can guide development strategies in this class.
-
Patent clearance searches should consider the overlap with older patents and active patents covering specific formulations or treatment protocols.
-
Companies should monitor remaining patent protections on newer bisphosphonates to assess freedom to operate, especially for nitrogen-containing derivatives.
Key Takeaways
-
U.S. Patent 4,677,191 covers a class of bisphosphonate compounds primarily used for bone resorption diseases, including specific chemical structures and synthesis methods.
-
Its claims are narrowly tailored to particular chemical substitution patterns and associated therapeutic applications.
-
The patent landscape has evolved with overlapping patents that focus on specific chemical modifications, formulations, and uses.
-
Expiration of key patents opens markets for generics, while newer patents emphasize indications, dosing, and delivery methods.
FAQs
1. When did U.S. Patent 4,677,191 expire?
It was granted in 1987 and expired in 2004, after a 17-year term recommended by patent law at the time.
2. Are newer bisphosphonate drugs protected by patents related to this one?
Many later patents focus on specific nitrogen-containing derivatives, formulations, or indications, and some are still active, targeting improvements in efficacy and safety.
3. How does the scope of this patent compare to later patents on bisphosphonates?
It covers a specific chemical class with limited substitution patterns, while later patents often focus on particular compounds, use methods, or formulations, offering narrower or broader protection.
4. Can generic versions of bisphosphonates like alendronate be produced now?
Most foundational patents, including U.S. 4,677,191, have expired, enabling generic manufacturing, provided no new patents covering the specific product are in force.
5. What strategic insights can companies gain from this patent landscape?
Understanding historical patent scope helps identify opportunities for innovation beyond existing claims, design around protected compounds, and recognize patent expiration timelines for market entry.
References
[1] U.S. Patent No. 4,677,191. (1987). "Bisphosphonate compounds."
[2] U.S. Patent No. 5,043,342. (1991). "New Bisphosphonate Compounds."
[3] U.S. Patent No. 4,876,242. (1989). "Treatment of Bone Disorders."
[4] U.S. Patent No. 4,927,814. (1990). "Use of Nitrogen-Containing Bisphosphonates."
